BRPI0410029A - dihidroquinazolinas substituìdas - Google Patents

dihidroquinazolinas substituìdas

Info

Publication number
BRPI0410029A
BRPI0410029A BRPI0410029-8A BRPI0410029A BRPI0410029A BR PI0410029 A BRPI0410029 A BR PI0410029A BR PI0410029 A BRPI0410029 A BR PI0410029A BR PI0410029 A BRPI0410029 A BR PI0410029A
Authority
BR
Brazil
Prior art keywords
substituted
dihydroquinazolines
preparation
substituted dihydroquinazolines
dihydroquinazolins
Prior art date
Application number
BRPI0410029-8A
Other languages
English (en)
Inventor
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Thomas Lampe
Susanne Nikolic
Juergen Reefschloger
Rudolf Schohe-Loop
Frank Suessmeier
Holger Zimeermann
Rolf Grosser
Kertin Henninger
Guy Hewlett
Joerg Keldenich
Dieter Lang
Peter Nell
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0410029A publication Critical patent/BRPI0410029A/pt
Publication of BRPI0410029B1 publication Critical patent/BRPI0410029B1/pt
Publication of BRPI0410029B8 publication Critical patent/BRPI0410029B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DIHIDROQUINAZOLINAS SUBSTITUìDAS". A invenção refere-se às dihidroquinazolinas substituídas e aos processos para sua a preparação, bem como seu uso para a preparação de medicamentos para o tratamento e/ou profilaxia de doenças, especialmente para o uso como agentes antivirais, especialmente contra citomegalovírus.
BRPI0410029A 2003-05-02 2004-04-17 composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto BRPI0410029B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
PCT/EP2004/004103 WO2004096778A1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften

Publications (3)

Publication Number Publication Date
BRPI0410029A true BRPI0410029A (pt) 2006-04-25
BRPI0410029B1 BRPI0410029B1 (pt) 2019-12-31
BRPI0410029B8 BRPI0410029B8 (pt) 2021-06-15

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410029A BRPI0410029B8 (pt) 2003-05-02 2004-04-17 composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto

Country Status (38)

Country Link
US (4) US7196086B2 (pt)
EP (1) EP1622880B3 (pt)
JP (1) JP4733631B2 (pt)
KR (1) KR100927063B1 (pt)
CN (1) CN100393706C (pt)
AR (1) AR044078A1 (pt)
AT (1) ATE355280T1 (pt)
AU (1) AU2004233978B2 (pt)
BR (1) BRPI0410029B8 (pt)
CA (1) CA2524069C (pt)
CL (1) CL2004000930A1 (pt)
CO (1) CO5700764A2 (pt)
CY (2) CY1106476T1 (pt)
DE (2) DE10319612A1 (pt)
DK (1) DK1622880T6 (pt)
EC (1) ECSP056138A (pt)
EG (1) EG25273A (pt)
ES (1) ES2284007T7 (pt)
FR (1) FR18C1029I2 (pt)
HN (1) HN2004000146A (pt)
HU (2) HUS1800018I1 (pt)
IL (1) IL171513A (pt)
MA (1) MA27794A1 (pt)
MX (1) MXPA05011707A (pt)
MY (1) MY144616A (pt)
NL (1) NL300933I2 (pt)
NO (2) NO333265B3 (pt)
NZ (1) NZ543317A (pt)
PE (1) PE20050145A1 (pt)
PL (1) PL1622880T6 (pt)
PT (1) PT1622880E (pt)
RU (1) RU2360912C2 (pt)
SI (1) SI1622880T1 (pt)
TW (1) TWI335912B (pt)
UA (1) UA82519C2 (pt)
UY (1) UY28294A1 (pt)
WO (1) WO2004096778A1 (pt)
ZA (1) ZA200508710B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
MD4673C1 (ro) * 2013-06-19 2020-11-30 Aicuris Anti-Infective Cures Gmbh Letermovir amorf şi forme preparative farmaceutice solide ale acestuia pentru administrare orală
WO2015088931A1 (en) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
WO2017091453A1 (en) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts
US10851112B2 (en) 2016-08-08 2020-12-01 Medshine Discovery Inc. Anti-HCMV virus compound
KR102423393B1 (ko) * 2018-02-08 2022-07-21 파에노 테라퓨틱스 씨오., 엘티디. 3,4-디하이드로티에노[3,2-d]피리미딘 화합물의 결정형 및 이의 제조방법
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
CN114667285B (zh) 2019-09-26 2025-08-08 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
AR121439A1 (es) * 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY39098A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
UY39097A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
WO2022038457A1 (en) 2020-08-17 2022-02-24 Lupin Limited A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
UY40078A (es) 2021-12-21 2023-06-30 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin
CN118974026A (zh) * 2022-04-01 2024-11-15 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223B (zh) * 2022-06-08 2026-06-05 博远医药(苏州)有限公司 一种杂环衍生物及其药物组合物、应用
AR134783A1 (es) 2023-12-21 2026-04-01 Aic246 Ag & Co Kg Sales diastereoméricas de aminoalcohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica
WO2026106929A1 (en) 2024-11-14 2026-05-21 Assembly Biosciences, Inc. Dihydroquinazolines useful as cytomegalovirus antiviral agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
PL351374A1 (en) 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
BR0209054A (pt) 2001-04-19 2004-04-20 Bayer Ag Arilsulfonamidas como agentes antivirais
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) * 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
BRPI0607306A2 (pt) * 2005-01-25 2009-08-25 Prolexys Pharmaceuticals Inc derivados de quinoxalina como agentes anti-tumor
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
MD4673C1 (ro) * 2013-06-19 2020-11-30 Aicuris Anti-Infective Cures Gmbh Letermovir amorf şi forme preparative farmaceutice solide ale acestuia pentru administrare orală

Also Published As

Publication number Publication date
AU2004233978A1 (en) 2004-11-11
FR18C1029I2 (fr) 2020-07-17
BRPI0410029B8 (pt) 2021-06-15
RU2005137276A (ru) 2006-07-27
MXPA05011707A (es) 2006-02-13
KR20060009883A (ko) 2006-02-01
IL171513A (en) 2011-11-30
KR100927063B1 (ko) 2009-11-13
EP1622880B1 (de) 2007-02-28
PL1622880T3 (pl) 2007-08-31
CY2018019I1 (el) 2018-12-12
RU2360912C2 (ru) 2009-07-10
ECSP056138A (es) 2006-04-19
AU2004233978B2 (en) 2010-02-11
HK1092463A1 (zh) 2007-02-09
PT1622880E (pt) 2007-06-04
CL2004000930A1 (es) 2005-03-18
CA2524069A1 (en) 2004-11-11
USRE46791E1 (en) 2018-04-17
DE10319612A1 (de) 2004-11-18
NZ543317A (en) 2008-05-30
DK1622880T3 (da) 2007-06-25
EP1622880B3 (de) 2018-05-23
EG25273A (en) 2011-12-04
US7196086B2 (en) 2007-03-27
NO20055649D0 (no) 2005-11-30
PE20050145A1 (es) 2005-05-22
CY2018019I2 (el) 2018-12-12
ES2284007T7 (es) 2018-06-20
CA2524069C (en) 2011-11-08
EP1622880A1 (de) 2006-02-08
ATE355280T1 (de) 2006-03-15
JP2006525249A (ja) 2006-11-09
US20070191387A1 (en) 2007-08-16
US8513255B2 (en) 2013-08-20
MY144616A (en) 2011-10-14
CY1106476T1 (el) 2012-01-25
NO2018022I1 (no) 2018-07-04
NL300933I2 (nl) 2018-04-26
DE502004003052D1 (de) 2007-04-12
SI1622880T1 (sl) 2007-08-31
NO333265B1 (no) 2013-04-22
UA82519C2 (uk) 2008-04-25
TWI335912B (en) 2011-01-11
NO20055649L (no) 2006-01-31
US20050065160A1 (en) 2005-03-24
HUS1800028I1 (hu) 2018-07-30
FR18C1029I1 (pt) 2018-08-17
TW200510343A (en) 2005-03-16
ES2284007T3 (es) 2007-11-01
NO333265B3 (no) 2019-06-03
BRPI0410029B1 (pt) 2019-12-31
JP4733631B2 (ja) 2011-07-27
PL1622880T6 (pl) 2018-08-31
CN100393706C (zh) 2008-06-11
CO5700764A2 (es) 2006-11-30
CN1784390A (zh) 2006-06-07
UY28294A1 (es) 2004-11-30
HN2004000146A (es) 2008-06-24
WO2004096778A1 (de) 2004-11-11
DK1622880T6 (da) 2018-06-18
USRE49698E1 (en) 2023-10-17
MA27794A1 (fr) 2006-03-01
ZA200508710B (en) 2006-12-27
AR044078A1 (es) 2005-08-24
HUS1800018I1 (hu) 2018-05-28

Similar Documents

Publication Publication Date Title
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
DOP2002000429A (es) Imidazotriazinas
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
HRP20040042B1 (hr) Supstituirani oksazolidinoni za kombinacijsku terapiju
BRPI0411900A (pt) compostos antivirais e métodos
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
UY27878A1 (es) Derivados de indolinfenilsulfonamida
BR0316680A (pt) Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
BR0111358A (pt) Compostos de tioacetamida e seu uso
ATE448232T1 (de) Substituierte heterozyklen
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
UY28313A1 (es) Nonadepsipeptidos acilados
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
BR0012291A (pt) Fenoxifluorpirimidinas
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
UY29189A1 (es) Nonadepsipeptidos acilados ii
BR0113204A (pt) uso de ácidos 3-benzoilfenilacéticos no tratamento de angiogênese e distúrbios relacionados à anciogênese
UY27733A1 (es) Derivados de ciclopenteno.
HN2006007774A (es) Imidazoles sustituidos con heterociclilamida
BR0210910A (pt) Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: AICURIS ANTI-INFECTIVE CURES GMBH (DE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2556 DE 31/12/2019 QUANTO AOS INVENTORES.

B25D Requested change of name of applicant approved

Owner name: AICURIS ANTI-INFECTIVE CURES AG (DE)

B25A Requested transfer of rights approved

Owner name: AIC246 GMBH AND CO. KG (DE)

B25D Requested change of name of applicant approved

Owner name: AIC246 AG AND CO. KG (DE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2823 DE 11-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.